Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Prevnar 20 in Healthy Infants
NCT04382326Phase 3Completed
- Sponsor
- Pfizer
- Start
- May 2020
- Primary completion
- Sep 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of Prevnar 20 in pneumococcal disease, invasive pneumococcal disease (IPD) and Pneumococcal pneumonia (PP) (2 arms), sponsored by Pfizer. Primary endpoints: Percentage of Participants With Local Reactions, Percentage of Participants With Systemic Events and 5 more. Started May 2020; status: completed.
02
Drugs
Prevnar 20
03
Conditions
pneumococcal diseaseinvasive pneumococcal disease (IPD)Pneumococcal pneumonia (PP)
Beyond the preview
Go deeper on NCT04382326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04382326.